Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value […]
Tag: CareDx
New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients
ISHLT Guidelines Recommend Earlier Use of AlloMap Heart Starting 2 Months Post-Transplant Based on Strength of Clinical Studies ISHLT Guidelines Recommend Remote Use of GEP and dd-cfDNA Heart Transplant Surveillance, as in HeartCare, May be Used to Reduce the Need […]
CareDx to Report Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the third quarter […]
CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care
CareDx Top-Tier Sponsor for Heart Failure Society of America Annual Scientific Meeting BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers […]
CareDx Congratulates Board Member Dr. Grace Colón for Being Named Healthcare Innovator on Top 50 Most Powerful Latinas List
The Association of Latino Professionals For America Recognizes the Most Powerful Latinas in Business, Technology, Healthcare, and Non-Profit Sectors BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value […]
CareDx Extends Artificial Intelligence Leadership to Heart Transplantation
New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of […]
CareDx Reports Over 200,000 Heart Transplant Patient Results Served
CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ […]
CareDx Partners with HeartBrothers Foundation to Help Patients Living with Heart Failure and Heart Transplant
SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that […]
CareDx Brings Together Leading Transplant Experts to Share Latest Advancements in the Field of Xenotransplantation
SOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that […]
CareDx Introduces AlloCell: Cell Therapy Surveillance
CareDx Announces Collaborations to Develop Cellular Therapy Diagnostics SOUTH SAN FRANCISCO, Calif., April 14, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for […]